Biocon, India’s leading and Asia’s premier biopharmaceutical enterprise has set up its first state-of-art overseas bio-pharma manufacturing and research facility located within a 40 acre compound, at Bio-XCell, Johor in Malaysia. With an investment of over USD 200 million, this is the largest foreign investment in the Biopharma sector in Malaysia. The facility once fully operational in 2016, will be the largest integrated insulin production plant in Asia. Biocon’s Malaysia facility will further augment its capabilities to cater to the global needs of diabetic patients for affordable insulin and insulin analogs. Biocon Malaysia offers an excellent career opportunity for biotech professionals.